Today, Sanofi and Regeneron announced that the European Commission has granted marketing authorization for the companies’ sarilumab (Kevzara), which is approved to treat severely active rheumatoid arthritis, and which outperformed Humira in a phase 3 trial.
Today, Sanofi and Regeneron announced that the European Commission (EC) has granted marketing authorization for the companies’ sarilumab (Kevzara), which is approved to treat severely active rheumatoid arthritis (RA) in adult patients who have either not tolerated or not responded adequately to disease modifying anti-rheumatic drugs (DMARDs). Sarilumab, which may be used jointly with methotrexate or as a monotherapy in patients who do not tolerate methotrexate, is also approved in the United States.
The EC’s approval of the human monoclonal antibody was based upon a positive opinion delivered by the European Medicine Agency’s Committee for Medicinal Products for Human Use, which evaluated results from 7 phase 3 trials that incorporated data from more than 3300 adults with moderately to severely active RA.
These trials included a phase 3 study that compared sarilumab monotherapy to adalimumab (AbbVie’s Humira) monotherapy; at 24 weeks of treatment, patients treated with sarilumab monotherapy demonstrated greater reduction in disease activity, greater improvement in baseline physical function, higher rates of remission, and greater improvement in the signs and symptoms of RA than did patients treated with adalimumab monotherapy.
In addition to news that sarilumab outperformed Humira in this trial, Sanofi and Regeneron have announced that the drug’s US list price of $39,000 represents a savings of roughly 30% relative to Humira and etanercept (Amgen’s Enbrel). The manufacturers are expected to adopt a similarly competitive pricing strategy in Europe in order to help increase sarilumab’s market share.
Such a move could put additional pressure on AbbVie, which has so far held dominance in the crowded anti-rheumatic drug market, to adjust the price of its blockbuster RA drug, Humira. Deemed cost-ineffective by the Institute for Clinical and Economic Review, Humira was responsible for 63% of AbbVie’s 2016 revenue, though challenges from biosimilar adalimumab treatments are expected to erode its earnings in the coming years. While AbbVie seeks new inroads into the RA marketplace with such innovative drugs as its upadacitinib (ABT-494), AbbVie will be unable to rely on that drug’s prospective launch alone. The manufacture will have to develop strategies to better compete with small-molecule and biosimilar drugs alike in an increasingly crowded RA landscape.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.